Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations
Claudia Maria Trombetta, Giulia Piccini, Giulio Pierleoni, Margherita Leonardi, Francesca Dapporto, Serena Marchi, Emanuele Andreano, Ida Paciello, Linda Benincasa, Piero Lovreglio, Nicola Buonvino, Nicola Decaro, Angela Stufano, Eleonora Lorusso, Emilio Bombardieri, Antonella Ruello, Simonetta Viviani, Rino Rappuoli, Eleonora Molesti, Alessandro Manenti, Emanuele Montomoli
Abstract
The SARS-CoV-2 Omicron variant has rapidly replaced the Delta variant of concern. This new variant harbors worrisome mutations on the spike protein, which are able to escape the immunity elicited by vaccination and/or natural infection. To evaluate the impact and susceptibility of different serum samples to the Omicron variant BA.1, samples from COVID-19 patients and vaccinated individuals were tested for their ability to bind and neutralize the original SARS-CoV-2 virus and the Omicron variant BA.1. COVID-19 patients show the most drastic reduction in Omicron-specific antibody response in comparison with the response to the wild-type virus. Antibodies elicited by a triple homologous/heterologous vaccination regimen or following natural SARS-CoV-2 infection combined with a two-dose vaccine course, result in highest neutralization capacity against the Omicron variant BA.1. Overall, these findings confirm that vaccination of COVID-19 survivors and booster dose to vaccinees with mRNA vaccines is the correct strategy to enhance the antibody cross-protection against Omicron variant BA.1.